Analysis of Hong Kong IVF Third-Generation Technology: PGT Indications and Clinical Choices
Hong Kong's third-generation IVF technology (PGT) is primarily used for specific populations such as those with chromosomal abnormalities, single-gene disorders, and recurrent miscarriage. The technical system is mature but has strict indications. This article analyzes PGT technology principles, applicable conditions, procedures, and regional differences from a clinician's perspective, helping decision-makers rationally evaluate technological choices.
Clinical Positioning of Third-Generation IVF Technology
In clinical decision-making within reproductive medicine, whether to adopt third-generation IVF technology (PGT) depends on a systematic assessment of the patient's genetic risk. Hong Kong's third-generation IVF technology (PGT) has formed a relatively mature system in clinical application, but its applicability and effectiveness depend on specific medical indications. The core value of PGT lies in identifying embryos with chromosomal or gene abnormalities before embryo transfer, thereby reducing the risk of transmitting genetic diseases or improving implantation efficiency.
Three Types of PGT Technology and Their Indications
| Technology Type | Detection Target | Main Indications |
|---|---|---|
| PGT‑A | Chromosomal aneuploidy screening | Advanced maternal age, recurrent miscarriage, recurrent implantation failure |
| PGT‑M | Single-gene disease detection | Carriers of known single-gene genetic disorders |
| PGT‑SR | Chromosomal structural rearrangement detection | Balanced translocation, Robertsonian translocation, inversion, etc. |
PGT‑A is currently the most widely used third-generation IVF technology, primarily used to screen embryos for chromosomal numerical abnormalities. PGT‑M and PGT‑SR target specific genetic issues and require a known genetic diagnosis as a prerequisite.
How Clinicians Determine the Need for PGT
In reproductive clinical practice, recommending PGT is based on the presence of clear medical indications, not as a routine option for all IVF patients.
Clear Genetic Indications are a Prerequisite
Conditions suitable for PGT:
- Female age ≥ 38 years, with significantly increased risk of embryonic aneuploidy
- Previous history of pregnancy with chromosomal abnormalities
- One partner has a chromosomal structural rearrangement
- Carrier of a known single-gene genetic disorder
- Recurrent spontaneous miscarriage (≥ 2 times) where embryonic chromosomal factors are considered after investigation
- Recurrent implantation failure (≥ 3 transfers of good-quality embryos without pregnancy)
Not Recommended for Routine Use in All IVF Patients
Conditions unsuitable or not requiring routine PGT:
- Age < 35 years, no genetic history, no adverse pregnancy history
- Low embryo count (e.g., only 1-2 blastocysts), where biopsy may cause embryo damage
- IVF primarily due to tubal factor or male factor, with no genetic risk
- Ethical or religious concerns regarding embryo biopsy
PGT does not increase the chance of every live birth. For non-indicated populations, PGT does not increase the cumulative live birth rate and may instead lead to the discarding of usable embryos due to biopsy.
Differences in Application Across Age Groups
Age is a key variable influencing the clinical value of PGT. The risk of embryonic aneuploidy varies significantly across different age groups, and the decision-making logic differs accordingly.
Under 35 Years
In this age group, the embryonic aneuploidy rate is relatively low (approximately 20-30%). Without a history of genetic disorders or recurrent miscarriage, the benefit of routine PGT‑A is limited. Clinicians typically recommend its use only for specific indications.
35-40 Years
The embryonic aneuploidy rate rises to 30-50%. PGT‑A has a clearer screening value in this age group, reducing the risk of implantation failure and miscarriage due to chromosomal abnormalities. However, it must be evaluated in conjunction with the embryo count to avoid losing limited embryos due to biopsy.
Over 40 Years
The embryonic aneuploidy rate exceeds 50-60%, offering the greatest theoretical benefit from PGT‑A. However, this age group experiences a decline in oocyte yield and available embryos, potentially leading to a situation where "no embryos are available for transfer." Clinically, patients must be informed of this possibility in advance and alternative plans discussed.
Main Differences Between Hong Kong and Mainland China in Third-Generation IVF
There are several differences between Hong Kong and Mainland China in the application of third-generation IVF technology, which affect patient decision-making and medical pathways.
| Dimension of Difference | Hong Kong | Mainland China |
|---|---|---|
| Technology Access | Available at all qualified centers | Requires approval from the National Health Commission; limited number of centers |
| Indication Management | Medical indications + genetic counseling recommendations | Strict medical indications + administrative approval |
| Embryo Biopsy Technique | Laser-assisted biopsy widely used | Primarily laser-assisted biopsy |
| Testing Platform | Primarily NGS; some centers use aCGH | Primarily NGS |
| Sex Selection | Prohibited for non-medical reasons | Prohibited for non-medical reasons |
| Average Cost | Approximately HKD 80,000-120,000 | Approximately RMB 50,000-80,000 |
| Time Cycle | 1.5-2 months (including testing time) | 2-3 months (including approval time) |
Hong Kong introduced PGT technology into clinical practice earlier, and its laboratory quality control system is more aligned with international standards. Some large reproductive centers in Mainland China have reached international technical levels, but their number and accessibility are limited by policy.
Easily Overlooked Clinical Details
Clinical Management of Embryonic Mosaicism
Approximately 3-5% of embryos exhibit mosaicism (i.e., the presence of both normal and abnormal cell lines within the embryo). PGT biopsy typically samples 3-5 trophectoderm cells, carrying a risk of missing or misjudging mosaicism. Clinical management of mosaic embryos requires individualized decision-making based on the mosaic ratio, chromosome type, and patient condition, sometimes necessitating a second biopsy or genetic counseling.
Accuracy and Limitations of Testing Technology
The detection accuracy of PGT ranges from 95-98%, but it has the following limitations:
- Cannot detect all genetic diseases
- Possibility of false positives and false negatives
- Cannot assess non-genetic embryo quality (e.g., morphology, developmental potential)
- Special types such as mitochondrial diseases and imprinting disorders are not within the scope of routine testing
Necessity of Genetic Counseling
All patients considering PGT should receive genetic counseling, covering: systematic assessment of genetic risk, benefits and limitations of the testing technology, possible types of test results (normal, abnormal, mosaic, uncertain), and result interpretation along with subsequent decision-making options.
Actual Medical Procedure for Third-Generation IVF in Hong Kong
Initial Consultation and Assessment Phase
This requires completing: fertility assessment (AMH, FSH, antral follicle count), genetic screening (chromosomal karyotype analysis, carrier screening for genetic diseases), infectious disease screening, and semen analysis. This phase typically takes 1-2 weeks to complete tests and issue reports.
Ovarian Stimulation and Embryo Culture
An individualized ovarian stimulation protocol is used. After oocyte retrieval, intracytoplasmic sperm injection (ICSI) is performed, and embryos are cultured to the blastocyst stage (days 5-6). The blastocyst formation rate in most Hong Kong reproductive centers ranges from 40-60%.
Embryo Biopsy and Genetic Testing
At the blastocyst stage, 3-5 trophectoderm cells are biopsied. The sample is sent to a genetic laboratory for NGS testing. The testing cycle typically takes 7-14 working days. After biopsy, the blastocysts are cryopreserved by vitrification.
Frozen Embryo Transfer and Pregnancy Management
Blastocysts with normal test results are transferred in a subsequent cycle after freeze-thawing. A blood HCG test is performed 12-14 days after transfer to confirm pregnancy, followed by ultrasound monitoring. The entire cycle from initial consultation to transfer completion typically takes 2-3 months, with an embryo testing waiting period of about 1-2 weeks.
Frequently Asked Questions
Q: What genetic diseases can third-generation IVF in Hong Kong screen for?
PGT‑M can screen for single-gene diseases with clearly identified pathogenic genes, provided the pathogenic gene locus is known. PGT‑A screens for aneuploidy of all 23 chromosomes but cannot detect microdeletions or microduplications (which require specific microarrays).
Q: Does embryo biopsy for third-generation IVF damage the embryo?
Trophectoderm biopsy at the blastocyst stage has a minimal impact on the inner cell mass (which develops into the fetus), but the biopsy procedure itself carries a risk of embryo damage of about 1-2%. Current research shows no significant increase in birth defect rates among live births resulting from PGT.
Q: Can third-generation IVF guarantee a healthy baby?
No. PGT can reduce the risk of specific genetic diseases and chromosomal abnormalities but cannot rule out all birth defects. All newborns have a baseline risk of birth defects (approximately 2-3%), which PGT cannot alter.
Q: What documents are needed for third-generation IVF in Hong Kong?
Assisted reproductive technology in Hong Kong requires identification documents for both partners, marriage certificate, genetic counseling records, and proof of medical indications. Some centers require an ethics review.
Q: How long does third-generation IVF take in Hong Kong?
From initial consultation to completion of transfer, excluding waiting cycles, it typically takes 2.5-3 months. This includes approximately 2 weeks for ovarian stimulation, 5-6 days for embryo culture, 7-14 days for genetic testing, and about 2-4 weeks for the frozen embryo transfer cycle (depending on the endometrial preparation protocol).
Risk Reminder: PGT technology involves embryo biopsy and genetic testing, carrying the following risks that require attention: risk of embryo damage (approximately 1-2%); uncertain test results or mosaic results, potentially requiring repeat testing or re-biopsy; embryos need to be frozen during the testing period, and the freeze-thaw process may cause embryo loss (approximately 1-5%); risk of having no embryos available for transfer, especially in cases of advanced age or low embryo count; insufficient genetic counseling may lead to misunderstanding of test results; high cost, usually not covered by medical insurance.
Before deciding to undergo PGT, it is recommended to communicate thoroughly with your reproductive doctor and genetic counselor to clarify your personal indications, expected benefits, and potential risks.
PGT‑A PGT‑M PGT‑SR Embryonic Mosaicism Genetic Counseling Chromosomal Aneuploidy Single-Gene Disease Hong Kong Assisted Reproduction Embryo Biopsy NGS
0 comments